Sorrento has eight (8) potential Covid Emergency Use Authorization candidates...all Blockbusters! Here's a partial overview.
1. Covi-Stix rapid accurate virus test
2. Covi-Track rapid accurate antibody test
3. Covi-push 2020 injection
4. Covi-Drops 2020 nose drops
5. Covi-Vax 2020 lipid DNA injection($34 million DARPA funding)
6. Abivirtinib ARDS prevention
7. Covi-MSC Stem Cell ARDS treatment
8. Covi-Shield antibody cocktail(to deal with variants)
Each of these EUA's could be accompanied by government grants and multi-billion dollar international sales. Additionally there would be multi-billion dollar worldwide marketing partnerships. Dr.Ji says there is "humungous" interest from Mexico, Brazil and Europe.
Timing? Some could come in days. Some in weeks. Others in several months.
In addition to these 8 Covid EUA candidates Sorrento has other potential multi $Billion programs ... here are 2 samples from each of the three portfolio areas...with at least 3 with 2021 revenue potential!
NON-OPIOID PAIN
1. SP-102 phase 3 near 100% enrolled, fast track, lumbar/sciatic pain
2. RTX intractable cancer, knee and arthritic pain
COVID
1. rapid, accurate, low cost tests. TRACK, TRACE, STIX
2. 2020 DROPS, injection and plasmid DNA
CANCER
1. Abivirtinib NSCLC phase 3,lymphomas phase 2, prostate IND, lupus
2. SmartPharm plasmid DNA Plus CAR-T and DAR-T and Mayo Clinic ADNAB drugs.
In summary in 2021 I look forward to the advance and/or approval of all 3 Covid tests; all 3 delivery forms of 2020; all 3 uses of Abivirtinib; all 3 applications of RTX; and all 3 non-opioid pain treatments. In 2021 we will start to see the payoff of the SmartPharm , ACEA and Mayo Clinic technology acquisitions. And 2021 will see half a dozen EUA's, settlement of the PSS lawsuit, maturation of the Celularity and ImmunityBio investments, and several large government grants and the beginning of large scale cash flow.
"The refusal of the real is the number one dogma of our time" Rene Girard
